<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>1258</ReferenceId>
        <DateLastUpdated>2020-09-10-07:00</DateLastUpdated>
        <Article>
            <PubmedId>12902505</PubmedId>
            <Abstract>CTL escape mutations have been identified in several chronic infections, including mice infected with mouse hepatitis virus strain JHM. One outstanding question in understanding CTL escape is whether a CD8 T cell response to two or more immunodominant CTL epitopes would prevent CTL escape. Although CTL escape at multiple epitopes seems intuitively unlikely, CTL escape at multiple CD8 T cell epitopes has been documented in some chronically infected individual animals. To resolve this apparent contradiction, we engineered a recombinant variant of JHM that expressed the well-characterized gp33 epitope of lymphocytic choriomeningitis virus, an epitope with high functional avidity. The results show that the presence of a host response to this second epitope protected mice against CTL escape at the immunodominant JHM-specific CD8 T cell epitope, the persistence of infectious virus, and the development of clinical disease.</Abstract>
            <ArticleYear>2003</ArticleYear>
            <ArticlePages>2006-13</ArticlePages>
            <ArticleTitle>Protection against CTL escape and clinical disease in a murine model of virus persistence.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>Kim</LastName>
                    <ForeName>Taeg S</ForeName>
                </Author>
                <Author>
                    <LastName>Perlman</LastName>
                    <ForeName>Stanley</ForeName>
                </Author>
            </Authors>
            <Affiliations>Interdisciplinary Program in Immunology, Department of Pediatrics, University of Iowa, Iowa City, IA 52242, USA.</Affiliations>
            <ArticleChemicalList>Antigens, Viral;Epitopes, T-Lymphocyte;Glycoproteins;Peptide Fragments;Recombinant Fusion Proteins;Vaccines, Synthetic;Viral Proteins;glycoprotein peptide 33-41, Lymphocytic choriomeningitis virus</ArticleChemicalList>
            <ArticleMeshHeadingsList>Amino Acid Sequence; Animals; Antigens, Viral(administration &amp; dosage; analysis; biosynthesis; genetics); Chronic Disease; Coronavirus Infections(genetics; immunology; prevention &amp; control); Disease Models, Animal; Encephalomyelitis(genetics; immunology; prevention &amp; control; virology); Epitopes, T-Lymphocyte(administration &amp; dosage; analysis; biosynthesis; genetics); Female; Gene Deletion; Glycoproteins(administration &amp; dosage; analysis; biosynthesis; genetics); Hela Cells; Humans; Lymphocytic choriomeningitis virus(genetics; immunology); Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Molecular Sequence Data; Murine hepatitis virus(genetics; immunology); Peptide Fragments(administration &amp; dosage; analysis; biosynthesis; genetics); Recombinant Fusion Proteins(administration &amp; dosage; biosynthesis; chemical synthesis; immunology); T-Lymphocytes, Cytotoxic(immunology; metabolism; virology); Vaccines, Synthetic(administration &amp; dosage; biosynthesis; chemistry; immunology); Viral Proteins(administration &amp; dosage; analysis; biosynthesis; genetics); Virus Latency(genetics; immunology)</ArticleMeshHeadingsList>
            <Journal>
                <Volume>171</Volume>
                <Issue>4</Issue>
                <Title>Journal of immunology (Baltimore, Md. : 1950)</Title>
                <Issn>0022-1767</Issn>
                <MedlineTa>J Immunol</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeName>S510</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>CSLWNGPHL</LinearSequence>
                        <StartingPosition>510</StartingPosition>
                        <EndingPosition>518</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>YP_209233.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>11144</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Figure 1</LocationOfData>
                <EpitopeId>7032</EpitopeId>
                <ReferenceStartingPosition>510</ReferenceStartingPosition>
                <ReferenceEndingPosition>518</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <Assays>
                    <TCell>
                        <LocationOfData>Table II</LocationOfData>
                        <TCellId>21029</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                                <Age>10 days</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo to prevent or reduce disease</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>11138</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>recombinat murine hepatitis virus (strains: rJ+Sbf.gp33, rJ-Sbf.gp33, rJ+Sbf.g )</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intranasal</Route>
                                <DoseSchedule>1 dose(s) of 20000-60000 pfu in 12 ul</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Suckling mice were inoculated with a recombinant strain of mouse hepatitis virus (JHM) that contains gp33 (rJ+Sbf.gp33 or rJ-Sbf.gp33) or an analogue of gp33 that has an N-to-I mutation at position 37 (rJ+Sbf.gp33.N37I or rJ-Sbf.gp33.N37I). These were nursed by dams previously immunized with live wild-type murine hepatitis virus (JHM) preventing them from developing acute, fatal encephalitis; instead they developed a demyelinating encephalomyelitis with hindlimb paralysis several weeks post-infection.</ImmunizationComments>
                        </Immunization>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>recombinant murine hepatitis virus (strains: rJ+Sbf.gp33, rJ-Sbf.gp33, rJ+Sbf.g)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                <Object>
                                    <Organism>
                                        <SubType>Organism</SubType>
                                        <SourceOrganismId>11138</SourceOrganismId>
                                    </Organism>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Not determined</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>182</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>26</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>25</NumberOfSubjectsResponded>
                            <ResponseFrequency>96.2</ResponseFrequency>
                            <AssayComments>In the challenge assay, a virulent strain (JHM) of murine hepatitis virus was used as inoculant causing the disease. Non-progression towards clinical symptoms is considered protection. When incorporated (into murine hepatitis A virus JHM) as a second immunodominant epitope gp33 protected against CTL escape and disease development. (The percentage of asymptomatic (challenge protected) animals is lower when wildtype murine hepatitis virus is used compared to when recombinant murine hepatitis virus containing gp33 is used as an inoculant.) Using an analogue (anchor residue substitution, N-to-I at position 37) instead of gp33 conferred no protection.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 3A and 3B, Table I</LocationOfData>
                        <TCellId>21221</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                                <Age>6-weeks</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>11144</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intranasal</Route>
                                <DoseSchedule>1 dose(s) of 12 ul containing 60000 PFU</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Animals were inoculated with wildtype murine hepatitis virus. Lymphocytes for T-cell response analysis were obtained from brains of moribund mice (fatal encephalitis occurs at 7-8 days post-infection).</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Central nervous system (CNS)</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Central nervous system (CNS)</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>172</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>S510</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>CSLWNGPHL</LinearSequence>
                                        <StartingPosition>510</StartingPosition>
                                        <EndingPosition>518</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>YP_209233.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>11144</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>53</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Mice infected with wildtype murine hepatitis virus showed S510-specific CD8 T-cell responses.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table II</LocationOfData>
                        <TCellId>21214</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                                <Age>10 days</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo to prevent or reduce disease</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>11144</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Murine hepatitis virus (strain JHM)</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intranasal</Route>
                                <DoseSchedule>1 dose(s) of 20000-60000 pfu in 12 ul</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Suckling mice were inoculated with recombinant wildtype murine hepatitis virus (JHM). These were nursed by dams previously immunized with live wild-type murine hepatitis virus (JHM) preventing them from developing acute, fatal encephalitis; instead, they developed a demyelinating encephalomyelitis with hindlimb paralysis several weeks post-infection.</ImmunizationComments>
                        </Immunization>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Murine hepatitis virus (strain JHM)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Source Organism</EpitopeRelation>
                                <Object>
                                    <Organism>
                                        <SubType>Organism</SubType>
                                        <SourceOrganismId>11144</SourceOrganismId>
                                    </Organism>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Not determined</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>182</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>13</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>7</NumberOfSubjectsResponded>
                            <ResponseFrequency>53.8</ResponseFrequency>
                            <AssayComments>In the challenge assay, a virulent strain (JHM) of murine hepatitis virus  was used as inoculant. As it is known that a CTL response directed against the epitope occurs, progression towards clinical symptoms is considered an indication of CTL escape. Upon challenge not all animals became symptomatic, however, all symptomatic animals revealed mutations of the epitope whereas most asymptomatic animals had intact epitope. The percentage of asymptomatic (challenge protected) animals is lower when wildtype murine hepatitis virus is used compared to when recombinant murine hepatitis virus containing gp33 is used as an inoculant.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 3C and 3D, Table I</LocationOfData>
                        <TCellId>18358</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                                <Age>6-weeks</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>11144</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intranasal</Route>
                                <DoseSchedule>1 dose(s) of 12 ul containing 60000 PFU</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Animals were inoculated with recombinant virus that contained an extra immunodominant epitope (gp33) or its analogue (gp33.N37I). Lymphocytes for T-cell response analysis were obtained from brains of moribund mice (fatal encephalitis occurs at 7-8 days post-infection).</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Central nervous system (CNS)</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Central nervous system (CNS)</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>172</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>S510</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>CSLWNGPHL</LinearSequence>
                                        <StartingPosition>510</StartingPosition>
                                        <EndingPosition>518</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>YP_209233.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>11144</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>53</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Mice infected with recombinant virus that contained an extra immunodominant epitope (gp33) or its analogue (gp33.N37I) showed similar S510-specific CD8 T-cell responses.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>gp33</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>KAVYNFATC</LinearSequence>
                        <StartingPosition>33</StartingPosition>
                        <EndingPosition>41</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>AAA82178.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>11623</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Figure 1</LocationOfData>
                <EpitopeId>30001</EpitopeId>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <Assays>
                    <TCell>
                        <LocationOfData>Table II</LocationOfData>
                        <TCellId>21129</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                                <Age>10 days</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo to prevent or reduce disease</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>KAVYNFATC</LinearSequence>
                                            <StartingPosition>33</StartingPosition>
                                            <EndingPosition>41</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>AAA82178.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>11623</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>gp33</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <RecombinantOrganism>
                                        <SubType>Recombinant Organism</SubType>
                                        <RecombinantOrganismId>11138</RecombinantOrganismId>
                                    </RecombinantOrganism>
                                </ImmunogenContainingObject>
                                <Route>Intranasal</Route>
                                <DoseSchedule>1 dose(s) of 20000-60000 pfu in 12 ul</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Suckling mice were inoculated with a recombinant strain of mouse hepatitis virus that contains gp33 (rJ+Sbf.gp33 or rJ-Sbf.gp33) or an analogue of gp33 that has an N-to-I mutation at position 37 (rJ+Sbf.gp33.N37I or rJ-Sbf.gp33.N37I). These were nursed by dams previously immunized with live wild-type murine hepatitis virus (JHM) preventing them from developing acute, fatal encephalitis; instead, they developed a demyelinating encephalomyelitis with hindlimb paralysis several weeks post-infection. .</ImmunizationComments>
                        </Immunization>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>recombinant murine hepatitis virus (strains: rJ+Sbf.gp33, rJ-Sbf.gp33, rJ+Sbf.g)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Other</EpitopeRelation>
                                <Object>
                                    <Organism>
                                        <SubType>Organism</SubType>
                                        <SourceOrganismId>11138</SourceOrganismId>
                                    </Organism>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Not determined</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>182</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>In the challenge assay, a virulent strain (JHM) of murine hepatitis was used as inoculant, causing the disease. Non-progression towards clinical symptoms is considered protection. When incorporated (into murine hepatitis A virus JHM) as a second immunodominant epitope gp33 protected against CTL escape and disease development. (The percentage of asymptomatic (challenge protected) animals is lower when wildtype murine hepatitis virus is used compared to when recombinant murine hepatitis virus containing gp33 is used as an inoculant.) Using an analogue (anchor residue substitution, N-to-I at position 37) instead of gp33 conferred no protection.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 3C, Table I</LocationOfData>
                        <TCellId>18388</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                                <Age>6 weeks</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>KAVYNFATC</LinearSequence>
                                            <StartingPosition>33</StartingPosition>
                                            <EndingPosition>41</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>AAA82178.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>11623</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>gp33</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <RecombinantOrganism>
                                        <SubType>Recombinant Organism</SubType>
                                        <RecombinantOrganismId>11138</RecombinantOrganismId>
                                    </RecombinantOrganism>
                                </ImmunogenContainingObject>
                                <Route>Intranasal</Route>
                                <DoseSchedule>1 dose(s) of 12 ul containing 60000 PFU</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Animals were inoculated with a recombinant murine hepatitis virus carrying the epitope (gp33) or its analogue (gp33.N37I, sequence = KAVYIFATC). .</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Central nervous system (CNS)</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Central nervous system (CNS)</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>122</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>gp33</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>KAVYNFATC</LinearSequence>
                                        <StartingPosition>33</StartingPosition>
                                        <EndingPosition>41</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>AAA82178.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>11623</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>53</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>T-cell response to gp33 was robust but dependent on the level of expression of gp33. No epitope-specific response was observed with immunization using the recombinant murine hepatits A virus carrying the gp33 analogue (KAVYIFATC).</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

